Iovance Biotherapeutics, Inc.
IOVA
Rang in aandelen
#2887
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical... Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Aandeelprijs
$14.13
Laatst gesynchroniseerd: 2026-10-19
Marktkapitalisatie
$6.40B
Verandering (1 dag)
3.74%
Verandering (1 jaar)
509.05%
Land
US
Handel Iovance Biotherapeutics, Inc. (IOVA)
Categorie
Healthcare
EPS voor Iovance Biotherapeutics, Inc. (IOVA)
EPS per June 2026 TTM: $-0.73
Volgens de laatste financiële rapporten en de aandelenkoers van Iovance Biotherapeutics, Inc. is de huidige EPS van het bedrijf (TTM) $-0.73. Eind 2023 had het bedrijf een EPS van $-1.89, een daling ten opzichte van de EPS van 2022 die $-2.49 bedroeg.
EPS-geschiedenis van Iovance Biotherapeutics, Inc. van 2008 tot 2026
EPS aan het einde van elk jaar
| Jaar | EPS | Wijzigen |
|---|---|---|
| 2026 (TTM) | $-0.73 | -42.97% |
| 2024 | $-1.28 | -32.28% |
| 2023 | $-1.89 | -24.10% |
| 2022 | $-2.49 | 11.66% |
| 2021 | $-2.23 | 18.62% |
| 2020 | $-1.88 | 25.33% |
| 2019 | $-1.50 | 18.11% |
| 2018 | $-1.27 | -9.93% |
| 2017 | $-1.41 | 46.88% |
| 2016 | $-0.96 | 54.84% |
| 2015 | $-0.62 | 29.17% |
| 2014 | $-0.48 | -81.54% |
| 2013 | $-2.60 | -37.20% |
| 2012 | $-4.14 | -87.77% |
| 2011 | $-33.84 | 1,275.61% |
| 2010 | $-2.46 | 14,370.59% |
| 2009 | $-0.02 | -63.91% |
| 2008 | $-0.05 | 0.00% |
EPS van vergelijkbare bedrijven of concurrenten
| Bedrijf | EPS | EPS-verschil | Land |
|---|---|---|---|
| $17.32 | -2,472.60% |
US
|
|
| $-7.98 | 993.15% |
US
|
|
| $-5.29 | 624.66% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -3,900.00% |
NL
|
